Develops antifungal drugs for invasive candidiasis.
Jun 2026Revenue $19.2M/yrExpenses $41.8M/yr
No trendCash runway ≈ 4.1 years from Jun 2026
Figures by year
When will Scynexis be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $19.2M and expenses $41.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $20.6M | $36.7M | −$16.1M |
| Dec 2024 | $3.75M | $40.9M | −$37.1M |
| Dec 2023 | $140M | $67.5M | $72.7M |
| Dec 2022 | $5.09M | $90.8M | −$85.8M |
| Dec 2021 | $13.2M | $74.0M | −$60.8M |
| Dec 2020 | $0.00 | $51.1M | −$51.1M |
| Dec 2019 | $121K | $49.0M | −$48.9M |
| Dec 2018 | $257K | $30.2M | −$30.0M |
| Dec 2017 | $257K | $26.6M | −$26.3M |
| Dec 2016 | $257K | $28.1M | −$27.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.